Kawasaki-Syndrom mit Makrophagenaktivierung bei einem sechsjährigen Mädchen

• Literatur

• 1 McCrindle BW, Rowley AH, Newburger JW. et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation 2017; 135 (017) e927-e999
• 2 Capittini C, Emmi G, Mannarino S. et al. An immune-molecular hypothesis supporting infectious aetiopathogenesis of Kawasaki disease in children. European Journal of Immunology 2018; 48 (03) 543-545
• 3 Newburger JW, Takahashi M, Gerber MA. et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004; 110 (017) 2747-2771
• 4 Tremoulet AH, Jain S, Chandrasekar D. et al. Evolution of laboratory values in patients with Kawasaki disease. The Pediatric Infectious Disease Journal 2011; 30 (012) 1022-1026
• 5 Oates-Whitehead RM, Baumer JH, Haines L. et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children.. The Cochrane Database of Systematic Reviews 2003; (04) CD004000
• 6 Esteban YM, de Jong JLO, Tesher MS. An Overview of Hemophagocytic Lymphohistiocytosis. Pediatric Annals 2017; 46 (08) e309-e313
• 7 Sen ES, Clarke SL, Ramanan AV. Macrophage Activation Syndrome. Indian Journal of Pediatrics 2016; 83 (03) 248-253
• 8 Cron RQ, Davi S, Minoia F, Ravelli A. Clinical features and correct diagnosis of macrophage activation syndrome. Expert Review of Clinical Immunology 2015; 11 (09) 1043-1053
• 9 Lin CI, Yu HH, Lee JH. et al. Clinical analysis of macrophage activation syndrome in pediatric patients with autoimmune diseases. Clinical Rheumatology 2012; 31 (08) 1223-1230
• 10 Janka GE. Hemophagocytic syndromes. Blood Reviews 2007; 21 (05) 245-253
• 11 Dumont B, Jeannoel P, Trapes L. et al. [Macrophage activation syndrome and Kawasaki disease: Four new cases]. Archives de Pediatrie 2017; 24 (07) 640-646
• 12 Simonini G, Pagnini I, Innocenti L. et al. Macrophage activation syndrome/Hemophagocytic Lymphohistiocytosis and Kawasaki disease. Pediatric Blood & Cancer 2010; 55 (03) 592.
• 13 Latino GA, Manlhiot C, Yeung RS. et al. Macrophage activation syndrome in the acute phase of Kawasaki disease. Journal of Pediatric Hematology/Oncology 2010; 32 (07) 527-531
• 14 Atteritano M, David A, Bagnato G. et al. Haemo -phagocytic syndrome in rheumatic patients. A systematic Review. European Review for medical and pharmacological Sciences 2012; 16 (010) 1414-1424
• 15 Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. European Journal of Pediatrics 2007; 166 (02) 95-109
• 16 Ravelli A, Minoia F, Davi S. et al. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis & Rheumatology 2016; 68 (03) 566-576
• 17 Ravelli A. Macrophage activation syndrome. Current Opinion in Rheumatology 2002; 14 (05) 548-552
• 18 Henter JI, Horne A, Arico M. et al. HLH-2004: Diagnostic and therapeutic guidelines for hemo -phagocytic lymphohistiocytosis. Pediatric Blood & Cancer 2007; 48 (02) 124-131
• 19 Ravelli A, Magni-Manzoni S, Pistorio A. et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. The Journal of Pediatrics 2005; 146 (05) 598-604
• 20 Ohga S, Ooshima A, Fukushige J, Ueda K. Histiocytic haemophagocytosis in a patient with Kawasaki disease: changes in the hypercytokinaemic state. European Journal of Pediatrics 1995; 154 (07) 539-541
• 21 Wang W, Gong F, Zhu W. et al. Macrophage activation syndrome in Kawasaki disease: more common than we thought?. Seminars in Arthritis and Rheumatism 2015; 44 (04) 405-410
• 22 Titze U, Janka G, Schneider EM. et al. Hemophagocytic lymphohistiocytosis and Kawasaki disease: combined manifestation and differential diagnosis. Pediatric Blood & Cancer 2009; 53 (03) 493-495
• 23 Dogan V, Karaaslan E, Ozer S. et al. Hemophagocytosis in the Acute Phase of Fatal Kawasaki Disease in a 4 Month-Old Girl. Balkan medical Journal 2016; 33 (04) 470-472
• 24 Garcia-Pavon S, Yamazaki-Nakashimada MA, Baez M. et al. Kawasaki Disease Complicated With Macrophage Activation Syndrome: A Systematic Review. Journal of Pediatric Hematology/Oncology 2017; 39 (06) 445-451
• 25 Palazzi DL, McClain KL, Kaplan SL. Hemophagocytic syndrome after Kawasaki disease. The Pediatric Infectious Disease Journal 2003; 22 (07) 663-666
• 26 Chen Y, Shang S, Zhang C. et al. Hemophagocytic lymphohistiocytosis at initiation of kawasaki disease and their differential diagnosis. Pediatric Hematology and Oncology 2010; 27 (03) 244-249
• 27 Thabet F, Bellara I, Tabarki B. et al. [Ischemic colitis and hemophagocytosis complicating Kawasaki disease]. Archives de Pediatrie 2004; 11 (03) 226-228
• 28 Carter SJ, Tattersall RS, Ramanan AV. Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment. Rheumatology 2018 doi: 10.1093/rheumatology/key006. [Epub ahead of print]
• 29 Bar-Meir M, Kalisky I, Schwartz A. et al. Prediction of Resistance to Intravenous Immunoglobulin in Children With Kawasaki Disease. Journal of the Pediatric Infectious Diseases Society 2018; 7 (01) 25-29
• 30 Kim MK, Song MS, Kim GB. Factors Predicting Resistance to Intravenous Immunoglobulin Treatment and Coronary Artery Lesion in Patients with Kawasaki Disease: Analysis of the Korean Nationwide Multicenter Survey from 2012 to 2014. Korean Circulation Journal 2018; 48 (01) 71-79
• 31 Muise A, Tallett SE, Silverman ED. Are children with Kawasaki disease and prolonged fever at risk for macrophage activation syndrome?. Pediatrics 2003; 112 (6 Pt 1) e495